We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




AI Application in Pathology Reveals Novel Insights in Endometrial Cancer Diagnostics

By LabMedica International staff writers
Posted on 19 Dec 2022

Endometrial carcinoma is the most common cancer of the gynecologic tract. More...

Now, researchers have shown the power of artificial intelligence (AI) can be applied to endometrial carcinoma microscopy images, offering novel insights that could improve diagnosis and treatment of uterine cancer.

In the past years, researchers at Leiden University (Leiden, the Netherlands) had played a leading role in the development of a novel tumor classification system based on molecular alterations, resulting in four endometrial cancer subtypes. This time, the team set out to investigate if it was possible to predict these molecular classes, based on microscopy-images alone. The researchers applied artificial intelligence on microscopy images of thousands of endometrial carcinoma images from patients that participated in the study.

The team developed a model that robustly predicts the four molecular classes of endometrial carcinomas based on one (hematoxylin and eosin)-stained microscopy slide image, which is the standard histological stain used in diagnostics for assessment of tumor grading and histological subtyping. This model was not “a black-box”, but through reverse-engineering the researchers were able to show which image-features were relevant for its predictions. The model provided the team with important novel insights that can be utilized in future studies to further improve diagnostics, prognostication, and management of endometrial cancer patients.

“The application of AI in pathology is emerging,” said Dr. Tjalling Bosse at Leiden University. “In this project we studied the morphology of tumors that shared the same molecular alteration to better understand the effect these changes have on the appearance of the tumor. With this work, the computer model has directed us to areas in- and outside the tumor that are important.”

“In cancer diagnostics, the number of variables (molecular, tumor morphology, patient data) has increased exponentially and has complexified patient prognosis prediction,” added Sarah Fremond. “Through training unbiased AI models, AI predictions can also teach pathologists in return by, for instance, identifying novel morphological details on microscopy slide images with prognostic value.”

Related Links:
Leiden University


Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Homocysteine Quality Control
Liquichek Homocysteine Control
Urine Chemistry Control
Dropper Urine Chemistry Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more

Immunology

view channel
Image: The simple blood marker can predict which lymphoma patients will benefit most from CAR T-cell therapy (Photo courtesy of Shutterstock)

Routine Blood Test Can Predict Who Benefits Most from CAR T-Cell Therapy

CAR T-cell therapy has transformed treatment for patients with relapsed or treatment-resistant non-Hodgkin lymphoma, but many patients eventually relapse despite an initial response. Clinicians currently... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.